X
Tagrisso on target to be EGFR+ lung cancer standard
https://pharmaphorum.com/news/tagrisso-target-egfr-lung-cancer-standard/
NSCLC
Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer
September 6, 2017Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.
Evolving immunotherapy strategies in NSCLC
August 14, 2017Status of immunotherapies in non-small cell lung cancer (NSCLC).
ASCO 2017: Breast cancer next target for Keytruda
May 18, 2017Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
Novartis’ Zykadia gets fast first-line lung cancer review
February 24, 2017Roche rival has Breakthrough Therapy status.
Roche’s Alecensa approved in Europe, with head-to-head data coming
February 21, 2017Alecensa part of Roche’s goal of becoming dominant player in NSCLC
1 2
